# An Open-Label Extension Study to Evaluate the Safety of the ForSight VISION5 Product

> **NCT02143843** · PHASE2 · COMPLETED · sponsor: **ForSight Vision5, Inc.** · enrollment: 75 (actual)

## Conditions studied

- Primary Open-Angle Glaucoma
- Ocular Hypertension

## Interventions

- **DRUG:** Bimatoprost

## Key facts

- **NCT ID:** NCT02143843
- **Lead sponsor:** ForSight Vision5, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-06-05
- **Primary completion:** 2015-12-31
- **Final completion:** 2016-01-31
- **Target enrollment:** 75 (ACTUAL)
- **Last updated:** 2019-02-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02143843

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02143843, "An Open-Label Extension Study to Evaluate the Safety of the ForSight VISION5 Product". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT02143843. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*